SBHA|38937-66-5|(Suberohydroxamic acid; SBHA)-陌孚医药/Medlife

您当前的位置：

SBHA (Synonyms: Suberohydroxamic acid; SBHA)

目录号: PC10304 纯度: ≥98%

CAS No. :38937-66-5

商品编号	规格	价格	会员价	是否有货	数量
PC10304-50mg	50mg	¥980.00	请登录
PC10304-10mM (in 1mL DMSO)	10mM(in1mLDMSO)	¥637.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

SBHA

中文别名

软木肟酸;次异羟肟酸

英文名称

SBHA

英文别名

Octanediamide,N1,N8-dihydroxy-;SuberoylBis-hydroxamicAcid;SBHA;Suberohydroxamic Acid;Suberoyl Bis-hydroxa;OCTANE-1,8-DIHYDROXAMIC ACID;N,N′-Dihydroxyoctanediamide;Suberoyl bis-hydroxamic acid;N1,N8-Dihydroxyoctanediamide;n,n'-dihydroxyoctanediamide;Suberic Bishydroxamate;Octanedioic acid bis-hydroxyamide;Suberoyl Bishydroxamic Acid;Suberodihydroxamic Acid;Suberoyl bis hydroxamic acid;Suberoic bis hydroxamic acid;Suberohydroxamic acid, 95%;hexane-1,6-dicarbohydroxamic acid;IDQPVOFTURLJPT-UHFFFAOYSA-N;IN1104;BDBM50115661;2052AH;AKO;s5905

Cas No.

38937-66-5

分子式

C₈H₁₆N₂O₄

分子量

204.22

包装储存

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) is a competitive and cell-permeable HDAC1 and HDAC3 inhibitor with ID₅₀ values of 0.25 μM and 0.30 μM, respectively.Suberoyl bis-hydroxamic acid renders MM cells susceptible to apoptosis and facilitates the mitochondrial apoptotic pathways.Suberoyl bis-hydroxamic acid can be used for the study of medullary thyroid carcinoma (MTC).

性状

Solid

IC50 & Target[1][2]

HDAC1

0.25 μM (IC₅₀)

HDAC3

0.30 μM (IC₅₀)

体外研究(In Vitro)

Suberoyl bis-hydroxamic acid (10, 20 or 50 μM; 24 hours) combination with TRAIL improves apoptosis extent, and when TRAIL is combined with 20 μM SBHA (itself causing only 10–15% apoptosis), resulting in 45–50% cell death.
Suberoyl bis-hydroxamic acid (20-50 μM; 10-20 hours) alone has little effect on the expression of the proteins Bcl-xL, Mcl-1, and has albeit mildeffect on Bax. When it combines with TRAIL,which increases the ratio of relative protein expression of Bcl-xL and Bax in early periods, while the change in the ratio of Mcl-1 and Bax increases later in MM-BI and Ist-Mes2 cells.
Suberoyl bis-hydroxamic acid (30 μM; 6 hours) causes accumulation of acetylated histone H4 in MEL cells.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	MM-BI and Ist-Mes2 cells
Concentration:	10 μM, 20 μM or 50 μM
Incubation Time:	24 hours
Result:	Showed a cooperative effect in cell apoptosis.

体内研究(In Vivo)

Suberoyl bis-hydroxamic acid (intraperitoneal injection; 200 mg/kg; every 2 days; 12 days) reveals a marked increase in the active form of Notch1 (NICD) with a concomitant decrease in ASCL1. It reduces the MTC tumor growth.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice injected with human MTC cells
Dosage:	200 mg/kg
Administration:	Intraperitoneal injection; every 2 days; 12 days
Result:	Resulted in an average 55% inhibition of tumor growth in SBHA treatment group.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

[1]. Jiri Neuzil, et al. Sensitization of Mesothelioma to TRAIL Apoptosis by Inhibition of Histone Deacetylase: Role of Bcl-xL Down-Regulation. Biochem Biophys Res Commun. 2004 Jan 30;314(1):186-91. [Information]

[2]. V M Richon, et al. A Class of Hybrid Polar Inducers of Transformed Cell Differentiation Inhibits Histone Deacetylases.Proc Natl Acad Sci U S A [Information]

[3]. Li Ning, et al. Suberoyl Bishydroxamic Acid Activates notch1 Signaling and Suppresses Tumor Progression in an Animal Model of Medullary Thyroid Carcinoma. Ann Surg Oncol. 2008 Sep;15(9):2600-5. [Information]

溶解度数据

体外研究:

DMSO : 50 mg/mL (244.83 mM; Need ultrasonic)

H₂O : 8.33 mg/mL (40.79 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.8967 mL	24.4834 mL	48.9668 mL
5 mM	0.9793 mL	4.8967 mL	9.7934 mL
10 mM	0.4897 mL	2.4483 mL	4.8967 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： PBS
Solubility: 5 mg/mL (24.48 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
2.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.24 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
3.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.24 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation